Compare Ginkgo Bioworks Holdings Inc (DNA) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Morgan Stanley — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Morgan Stanley trades at $230.5 (market cap $359.10B). The key difference: Morgan Stanley is far larger — about 608.1× Ginkgo Bioworks Holdings Inc's market cap, and Morgan Stanley pays a 1.76% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MS | |
|---|---|---|
Market Cap | $590.53M | $359.10B |
Sector | Health | Financials |
52-Week High | $16.14 | $228.17 |
52-Week Low | $5.48 | $139.09 |
Enterprise Value | $627.78M | — |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Morgan Stanley (MS) trades at $228.17, up 2.65% on the day, with strong bullish momentum from three consecutive quarterly earnings beats. The stock shows robust revenue growth, reaching $66.0B in 2025, and a net income margin of 25.56%. Technical indicators signal a bullish trend, with moving averages supporting upward movement, while RSI levels suggest mixed short-term momentum. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management, reinforcing its market position.
Outlook remains positive with analyst consensus favoring Buy ratings (53.85%) and a price target of $225.80, slightly below current levels. Key opportunities include continued earnings outperformance and strategic initiatives in AI and IPO leadership. Risks involve volatile cash flows, high debt levels, and macroeconomic sensitivity. Investors should weigh strong fundamentals against execution risks in a dynamic financial landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
